抗体药物偶联物市场增长、规模、份额、趋势、关键参与者分析及 2031 年预测

  • Report Code : TIPRE00003494
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 293
Buy Now

抗体药物偶联物市场规模预计将从 2023 年的 81.0565 亿美元增至 2031 年的 380.7745 亿美元。预计 2023-2031 年市场复合年增长率将达到 21.3%。扩大临床试验渠道可能会在未来几年为市场带来新的趋势。

抗体药物偶联物市场分析

监管环境已发展到支持抗体-药物偶联物更快获批的程度。监管机构越来越认识到这些疗法的独特优势,从而简化了有前途的候选药物的审批流程。这种转变在上市时间可能对产品的商业成功产生重大影响的市场中至关重要。因此,获批抗体-药物偶联物的供应增加、研发投入增加、获批适应症扩大、支持性监管框架以及对靶向生物疗法的需求不断增长推动了市场的增长。随着对更有效和更有针对性的治疗方案的需求不断增长,制药公司和生物技术公司正在将大量资源投入到抗体-药物偶联物的研发中。辉瑞公司、基因泰克、吉利德科学和许多其他制药公司在抗体-药物偶联物开发项目上投入了大量资金。根据 Novotech 的数据,从 2018 年到 2022 年,全球有超过 900 项由行业发起的正在进行的抗体-药物偶联物试验;亚太地区占这些试验的三分之一以上。除美国和欧洲外,中国大陆、韩国、澳大利亚、日本和台湾是参与最多的亚洲地区,其中近 60% 的亚洲试验由中国大陆主导。因此,强劲的研发投资预计将在未来为抗体药物偶联物市场带来重大趋势。

抗体药物偶联物市场概况

抗体药物偶联物市场正在经历强劲增长,这得益于靶向治疗的进步和对肿瘤学的投资增加。整合连接体化学和有效载荷开发等创新技术对于提高抗体药物偶联物的性能至关重要。此外,在针对自身免疫性疾病以及癌症以外的其他疾病的临床试验中,ADC 候选药物的不断扩大预示着光明的未来。总体而言,ADC 市场有望大幅扩张,这反映了现代医学向更精准、更有效的治疗选择的转变。美国食品药品监督管理局 (FDA) 于 2022 年 12 月因严重的眼部毒性问题撤回了 Blenrep (belantamab mafodotin),这对多发性骨髓瘤治疗领域产生了重大影响。总体而言,该产品的损失可能会阻碍肿瘤学领域的创新和投资,从而影响长期增长前景。

目前有几种抗体-药物偶联物正处于 3 期试验阶段,重点是验证其在更大患者群体中的疗效和安全性。2028 年之前,处于 3 期试验阶段的 ADC 将上市,这将极大地重塑肿瘤学格局,为患者提供创新的治疗选择,并可能增加市场收入。

定制此报告以满足您的需求

您可以免费定制任何报告,包括本报告的部分内容、国家级分析、Excel 数据包,以及为初创企业和大学提供优惠和折扣

抗体药物偶联物市场:

Antibody Drug Conjugates Market
  • 获取此报告的关键市场趋势。
    这个免费样品将包括数据分析,从市场趋势到估计和预测。

抗体药物偶联物市场驱动因素和机遇

核准产品供应增加推动市场增长

对抗体-药物偶联物的投资有助于发现新的治疗靶点,并加速开发比传统疗法更有效、副作用更少的创新抗体-药物偶联物。新产品的获批增强了患者的治疗选择,特别是在肿瘤学领域,抗体-药物偶联物越来越多地被认可用于将细胞毒性药物直接递送至癌细胞,从而最大限度地减少对健康组织的损害。2024 年 4 月,辉瑞公司和 Genmab A/S 获得了 FDA 对 TIVDAK(tisotumab vedotin-TFTV)补充生物制品许可申请 (sBLA) 的全面批准,用于治疗化疗期间或化疗后病情进展的复发性或转移性宫颈癌患者。

现有抗体-药物偶联物获批适应症的扩大也为市场增长做出了重大贡献。随着更多适应症获得批准,这些疗法的潜在患者群体将增加,从而带来更高的销售额和市场渗透率。此外,这一趋势还通过创建促进创新和新产品批准的正反馈循环,扩大了市场规模并鼓励进一步研发。2023 年 10 月,第一三共与默克公司就第一三共的 DXd 抗体-药物偶联物候选药物签订了全球开发和商业化协议:patritumab deruxtecan (HER3-DXd)、ifinatamab deruxtecan (I-DXd) 和 raludotatug deruxtecan (R-DXd)。两家公司将在全球范围内联合开发并潜在地商业化这些抗体-药物偶联物候选药物,但日本除外,第一三共将在日本保留独家权利。第一三共将全权负责制造和供应。

拓展新适应症以创造重大增长机会

抗体-药物偶联物新适应症的扩展为抗体-药物偶联物市场创造了重大机遇。由于抗体-药物偶联物主要用于将细胞毒性药物直接递送至癌细胞,同时不损伤健康组织,因此其能够靶向特定肿瘤相关抗原,因此用途十分广泛。这种用途使得抗体-药物偶联物的应用范围可以扩展到其最初的适应症之外,即血液系统恶性肿瘤和某些实体肿瘤。

目前,许多癌症缺乏足够的治疗选择,而针对新生物标志物的抗体-药物偶联物可以作为针对这些具有挑战性的疾病的创新疗法。例如,抗体-药物偶联物正在被研究用于治疗乳腺癌、肺癌和膀胱癌等,而传统疗法可能无法产生令人满意的效果。阿斯利康和第一三共的 datopotamab deruxtecan (Dato-DXd) 生物制品许可申请 (BLA) 已在美国获得批准,用于治疗已接受过局部晚期或转移性非鳞状非小细胞肺癌 (NSCLC) 全身治疗的成年患者。

制药公司与研究机构之间的合作促进了抗体-药物偶联物开发的进一步创新。这些合作伙伴关系通常侧重于识别新靶点和优化连接技术,以提高偶联物的功效和安全性。此外,随着新靶点的发现和验证,抗体-药物偶联物正在进一步研究其在治疗更广泛癌症类型中的潜在用途。2024 年 6 月,致力于加速创新生物制药疗法开发的临床阶段公司 ArriVent BioPharma, Inc. 与 Alphamab Oncology 的全资子公司江苏 Alphamab Biopharmaceuticals Co., Ltd. 达成合作协议,以发现、开发和商业化用于治疗癌症的新型抗体-药物偶联物。抗体-药物偶联物有望通过利用癌症患病率的上升、解决未满足的医疗需求和促进合作创新,在未来的靶向癌症治疗中发挥关键作用。因此,扩展新的适应症为抗体药物偶联物市场提供了丰富的机会。

抗体药物偶联物市场报告细分分析

有助于得出抗体药物偶联物市场分析的关键部分是技术、应用、目标、分销渠道和地理。

  • 根据技术,抗体药物偶联物市场分为可裂解连接体和不可裂解连接体。可裂解连接体部分在 2023 年占据了较大的市场份额,预计在 2023-2031 年期间将实现显著的复合年增长率。
  • 根据应用,抗体药物偶联物市场细分为血癌、脑癌、乳腺癌、卵巢癌、肺癌等。乳腺癌领域在 2023 年占据了最大的市场份额。
  • 根据靶标,抗体药物偶联物市场细分为 HER2、CD22、CD30 等。HER2 细分市场在 2023 年占据了最大的市场份额,预计在 2023-2031 年期间将实现显着的复合年增长率。
  • 根据分销渠道,抗体药物偶联物市场分为零售药店、医院药店和在线药店。医院药店在 2023 年占据了最大的市场份额,预计在 2023-2031 年期间将实现显着的复合年增长率。

抗体药物偶联物市场份额按地区分析

抗体药物偶联物市场报告的地理范围分为五个主要区域:北美、欧洲、亚太地区、中东和非洲以及南美和中美洲。北美在 2023 年占据了市场主导地位。癌症发病率的迅速上升是推动这些国家对抗体药物偶联物需求的主要因素。此外,该地区的市场增长归因于研发的增加;产品批准的增加;对新型偶联物的认识不断提高;以及合并、合作和伙伴关系的激增。美国批准的抗体药物偶联物数量最多。美国正在研发几种抗体药物偶联物。已经开发了几种具有先进偶联物和接头技术、更有效的有效载荷和新的抗原靶标的偶联物。根据 FDA 于 2021 年 5 月发布的数据,113 项临床试验正在研究 77 种新型抗体药物偶联物,这些偶联物针对 40 多个不同的靶点。截至 2021 年 1 月,美国 FDA 已批准 Mylotarg、Lumoxiti、Adcetris、Kadcyla、Enhertu、Trodelvy、Besponsa、Polivy、Padcev 和 Blenrep 用于多种癌症适应症。2021 年 9 月,FDA 加快批准了由 Seagen 和 Genmab 开发的 Tivdak (tisotumab vedotin-tftv)。这种治疗方法是一种结合组织因子导向抗体和微管抑制剂的结合物。它以静脉输注的方式给药,适用于化疗期间或化疗后病情进展的复发性或转移性宫颈癌女性。此外,2023 年,阿斯利康的 Truqap(capivasertib)和 Faslodex(氟维司群)在美国获得监管部门批准,用于治疗患有生物标志物改变(PIK3CA、AKT1 或 PTEN)的 HR 阳性和 HER2 阴性局部晚期或转移性乳腺癌的成年患者。

美国抗体药物偶联物市场各公司不断开展业务扩张活动,以加强其在不同地区的市场地位,进一步支持了市场增长。2020 年 9 月,默克公司宣布了一项扩建计划,以扩大其位于威斯康星州麦迪逊的工厂的高效活性药物成分 (HPAPI) 和抗体药物偶联物制造能力,估值为 6,202 万美元(5,900 万欧元)。通过这项投资,该公司旨在加强用于癌症治疗的强效化合物的大规模生产,同时在预计于 2022 年中期完工后,从 2021 年开始创造约 50 个全职工作岗位。

 

抗体药物偶联物市场区域洞察

Insight Partners 的分析师已详细解释了预测期内影响抗体药物偶联物市场的区域趋势和因素。本节还讨论了北美、欧洲、亚太地区、中东和非洲以及南美和中美洲的抗体药物偶联物市场细分和地理位置。

Antibody Drug Conjugates Market
  • 获取抗体药物偶联物市场的区域特定数据

抗体药物偶联物市场报告范围

报告属性细节
2023 年的市场规模81.0565亿美元
2031 年市场规模380.7745亿美元
全球复合年增长率(2023 - 2031)21.3%
史料2021-2022
预测期2024-2031
涵盖的领域按技术分类
  • 可裂解接头
  • 不可切割接头
按应用
  • 血癌
  • 脑癌
  • 乳腺癌
  • 卵巢癌
  • 肺癌
按目标
  • HER2
  • CD22
  • CD30
按分销渠道
  • 零售药店
  • 医院药房
  • 网上药店
覆盖地区和国家北美
  • 我们
  • 加拿大
  • 墨西哥
欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
亚太
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
市场领导者和主要公司简介
  • ADC 治疗公司
  • 辉瑞公司
  • F. 霍夫曼-罗氏有限公司
  • 第一三共株式会社
  • 葛兰素史克公司
  • 吉利德科学公司
  • 阿斯利康公司
  • 安斯泰来制药公司
  • 荣昌生物股份有限公司
  • 武田药品工业株式会社

 

抗体药物偶联物市场参与者密度:了解其对业务动态的影响

抗体药物偶联物市场正在快速增长,这得益于终端用户需求的不断增长,而这些需求又源于消费者偏好的不断变化、技术进步以及对产品优势的认识不断提高等因素。随着需求的增加,企业正在扩大其产品范围,进行创新以满足消费者的需求,并利用新兴趋势,从而进一步推动市场增长。

市场参与者密度是指在特定市场或行业内运营的企业或公司的分布情况。它表明在给定市场空间中,相对于其规模或总市场价值,有多少竞争对手(市场参与者)存在。

在抗体药物偶联物市场运营的主要公司有:

  1. ADC 治疗公司
  2. 辉瑞公司
  3. F. 霍夫曼-罗氏有限公司
  4. 第一三共株式会社
  5. 葛兰素史克公司
  6. 吉利德科学公司

免责声明上面列出的公司没有按照任何特定顺序排列。


Antibody Drug Conjugates Market

 

  • 了解抗体药物偶联物市场顶级关键参与者概况

抗体药物偶联物市场新闻和最新发展

抗体药物偶联物市场通过收集一级和二级研究后的定性和定量数据进行评估,其中包括重要的公司出版物、协会数据和数据库。以下列出了市场中的一些关键发展:

  • 阿斯利康在新加坡建造了一家专门生产抗体药物偶联物的制造工厂。该工厂价值 15 亿美元,将致力于改善其抗体药物偶联物产品组合的全球供应。抗体药物偶联物是一种先进的治疗方法,旨在利用靶向抗体将强效抗癌剂直接输送到癌细胞。(来源:阿斯利康,公司网站,2024 年 11 月)
  • 第一三共和阿斯利康在中国获得了 ENHERTU(曲妥珠单抗德鲁替康)的有条件批准。该治疗适用于患有 HER2(ERBB2)突变且已接受过全身治疗的不可切除、局部晚期或转移性 NSCLC 成人患者。全面批准将取决于确认性试验的结果。(来源:第一三共,公司网站,2024 年 10 月)

抗体药物偶联物市场报告覆盖范围和交付成果

“抗体药物偶联物市场规模和预测(2021-2031)”报告对以下领域进行了详细的市场分析:

  • 抗体药物偶联物市场规模及全球、区域和国家层面所有主要细分市场的预测
  • 抗体药物偶联物市场趋势以及市场动态,如驱动因素、限制因素和关键机遇
  • 详细的 PEST 和 SWOT 分析
  • 抗体药物偶联物市场分析涵盖主要市场趋势、全球和区域框架、主要参与者、法规和最新市场发展
  • 行业格局和竞争分析,涵盖市场集中度、热图分析、知名参与者以及抗体药物偶联物市场的最新发展
  • 详细的公司简介
  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is the expected CAGR of the antibody drug conjugates market?

The market is expected to register a CAGR of 21.3% during 2023–2031.

What are the factors driving the antibody drug conjugates market growth?

Strategic investments by key players and an increase in the availability of approved products are among the significant factors fueling the market growth.

What are the future trends in the antibody drug conjugates market?

Expanding clinical trial pipeline is expected to emerge as a prime trend in the market in the coming years.

Which are the leading players operating in the antibody drug conjugates market?

ADC Therapeutics SA, Pfizer Inc, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Co Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, Takeda Pharmaceutical Co Ltd, Merck KGaA, Johnson & Johnson, Bristol-Myers Squibb Co, BioNTech SE, and AbbVie Inc are among the key players in the market.

What would be the estimated value of the antibody drug conjugates market by 2031?

The antibody drug conjugates market value is expected to reach US$ 38,077.45 million by 2031.

Trends and growth analysis reports related to Life Sciences : READ MORE..   
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

The List of Companies - Antibody Drug Conjugates Market

  1. ADC Therapeutics SA
  2. Pfizer Inc
  3. F. Hoffmann-La Roche Ltd
  4. Daiichi Sankyo Co Ltd
  5. GSK Plc
  6. Gilead Sciences Inc
  7. AstraZeneca Plc
  8. Astellas Pharma Inc
  9. RemeGen Co Ltd
  10. Takeda
  11. Pharmaceutical Co Ltd
  12. Merck KGaA
  13. Johnson & Johnson
  14. Bristol-Myers Squibb Co
  15. BioNTech SE
  16. AbbVie Inc

Buy Now  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.